NCT01477489已完成1 期
A Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 5
- 主要终点
- To determine the maximum tolerated dose of veliparib that can be administered concurrently with standard doses of radiotherapy to the chest wall and regional nodes.
研究概览
简要总结
The purpose of this study is to determine the maximum tolerated dose of veliparib that can be given while a patient is receiving radiation therapy.
详细描述
Veliparib is an investigational drug known as a "PARP inhibitor." Because veliparib affects the way that cells repair damage, veliparib may be useful in combination with radiation treatment because it may help make radiation work better. Veliparib is an oral medication that will be taken twice daily during the 6 weeks a patient is receiving radiation therapy. The researchers will also be analyzing blood and tissue taken from the skin of patients. The skin biopsies will help determine which patients are more sensitive to treatment with radiation combined with the study drug. While the blood sample will allow researchers to see if the way a person's body processes drugs affects how the patient responds to treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed breast cancer with either a) locoregional recurrence after previous mastectomy or b) inflammatory breast cancer status post mastectomy for which radiotherapy to the chest wall and regional nodes is planned as part of treatment. Patients with Stage IV disease are eligible as long as they meet these criteria.
- •Surgical resection of disease and willingness to wait at least three weeks after surgery to begin radiotherapy.
- •Willingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy, biologic therapy, and targeted therapies (including trastuzumab) at least two weeks prior to start of radiotherapy.
- •Age >18 years.
- •ECOG performance status <2 (Karnofsky >60%, see Appendix A).
- •Life expectancy of greater than 6 months.
- •Adequate hematologic, renal and hepatic function (assessed within the two weeks prior to registration and within the month prior to the commencement of protocol treatment).
- •Negative pregnancy test (within two weeks prior to registration) if woman has child-bearing potential (defined as not having undergone surgical methods of sterilization and having had menses within the past year).
- •Ability to swallow and retain oral medications.
- •Willingness to undergo the three required skin punch biopsies for research purposes.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Radiation therapy: Prior history of radiation therapy to the chest wall and/or regional nodes is not allowed (but prior radiation therapy to other sites is permissible).
- •Breast reconstruction: Patients who have undergone breast reconstruction procedures after mastectomy are excluded because of concerns about additional toxicity in this patient population.
- •Gross residual tumor or positive microscopic margins: Patients with gross residual tumor or positive microscopic margins will not be eligible because radiation dose in this study will be limited to 60Gy.
- •Ongoing therapy with other investigational agents: Patients may not be receiving any other investigational agents.
- •Unresolved toxicity from other agents: Patients with unresolved or unstable, CTCAE v4 Grade 3 or greater toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment are not eligible.
- •Significant comorbidity: Also ineligible are patients with clinically significant and uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or neurological/psychiatric disease or disorder, including but not limited to: active uncontrolled infection; symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; any other illness condition(s) that could exacerbate potential toxicities, confound safety assessments, require excluded therapy for management, or limit compliance with study requirements.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib.
- •Concomitant anti-neoplastic treatment is not allowed during protocol treatment and should be completed at least 2 weeks prior to commencement of protocol treatment, with resolution of any associated acute toxicities, except that endocrine therapies and bisphosphonates are permitted without restriction even during protocol treatment.
- •Pregnant women are excluded from this study because radiation therapy has teratogenic and abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with veliparib, breastfeeding should be discontinued before the patient receives veliparib.
- •Patients with active seizure disorder or history of seizure, as well as patients with CNS metastases (unless CNS metastases have been stable after therapy for >3 months and the patient is not on steroids at the time of study enrollment).
研究组 & 干预措施
Treatment
Experimental
干预措施: Veliparib (Drug)
Treatment
Experimental
干预措施: Standard radiation treatment (Radiation)
结局指标
主要结局
To determine the maximum tolerated dose of veliparib that can be administered concurrently with standard doses of radiotherapy to the chest wall and regional nodes.
时间窗: 12-24 months
次要结局
- To describe the nature of toxicity that develops when PARP inhibitors are administered concurrently with chest wall radiotherapy.(12-24 months)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT01063816AbbVie (prior sponsor, Abbott)79
已完成
1 期
Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerOvarian CancerNCT02483104AbbVie9
已完成
1 期
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT02944396AbbVie25
已完成
2 期
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung CancerBrain Metastases From Non-small Cell Lung CancerNCT01657799AbbVie (prior sponsor, Abbott)307
已完成
1 期
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid TumorsSolid TumorsNCT01617928AbbVie (prior sponsor, Abbott)12